Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

There is no cost or obligation for you to submit. No spam will be sent to your email.

$161,400,000 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$47.5 Million

QuantumScape Corporation

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

We combine specialized securities expertise with an innovative approach to litigation and an enduring commitment to our clients. We represent individuals, institutions, and asset managers in some of the largest, most complex securities cases in the country and never shy away from an uphill battle.

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

5

Days Left

BW

Babcock & Wilcox Enterprises, Inc.

Deadline

June 15 2026

Class Period

11/5/25 - 3/11/26

Allegations

(i) B&W’s largest shareholder, BRC, stood on both sides of the power generation contract and had close ties to B&W’s counterparty; (ii) Applied Digital did not need the products and services that B&W would purportedly supply pursuant to the power generation LNTP and contract; (iii) the foregoing, at the very least, would raise questions about the parties’ actual intent behind entering into the power generation LNTP and contract, including whether the Company is likely to recognize revenues from these agreements; (iv) accordingly, the business and financial prospects of the Company were overstated; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

11/5/25 - 3/11/26

Deadline

June 15 2026

Learn More

12

Days Left

LKQ

LKQ Corporation

Deadline

June 22 2026

Class Period

2/27/23 - 7/23/25

Allegations

According to the filed complaint, during the class period, defendants made materially false and misleading statements and omissions, and engaged in a scheme to deceive the market. This artificially inflated the price of LKQ common stock and operated as a fraud or deceit on the Class. Later, when defendants’ prior misrepresentations and fraudulent conduct were disclosed to the market, the price of LKQ common stock declined significantly as the prior artificial inflation came out over time. As a result of their purchases of LKQ common stock during the class period, members of the class suffered economic loss.

Class Period

2/27/23 - 7/23/25

Deadline

June 22 2026

Learn More

13

Days Left

RGC

Regencell Bioscience Holdings Limited

Deadline

June 23 2026

Class Period

10/28/24 - 10/31/25

Allegations

(i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

10/28/24 - 10/31/25

Deadline

June 23 2026

Learn More

13

Days Left

GLOB

Globant S.A.

Deadline

June 23 2026

Class Period

2/15/24 - 8/14/25

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that Globant’s Latin American operations began experiencing turmoil in late 2023. Latin America was not, as defendants claimed, a “particularly beneficial” region that would allow for the “ability to grow” Globant’s business. Nor was the market in Latin America “stable” or “improving a lot.” In truth, Globant was facing decreasing demand across Latin America and had frozen wages in both Argentina and Mexico in late 2023 and Latin American clients were reducing and cancelling their projects with the Company. Moreover, it was misleading for Globant to discuss the effects of the depreciation of the Argentine currency on its project contracts without disclosing that it had frozen the wages of its Argentine employees and that, because of currency depreciation, those wage freezes amounted in practical terms to wage cuts.

Class Period

2/15/24 - 8/14/25

Deadline

June 23 2026

Learn More

16

Days Left

SES

SES AI Corporation

Deadline

June 26 2026

Class Period

1/29/25 - 3/4/26

Allegations

(1) SES AI overstated its business prospects by materially overstating the expected results that could be achieved by deals with companies that have limited or no operations; (2) SES AI created an appearance of revenue by purchasing services in exchange for purchases of molecular universe; (3) Contrary to its positive statements regarding growth prospects, SES AI was affected by material logistics constraints in the fourth quarter of 2025 which would materially affect Q4 2025 revenues; (4) the foregoing called into question SES AI’s growth prospects for 2026, which were confirmed due to lower than expected 2026 revenue guidance; and (5) as a result, defendants’ statements about SES AI’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

1/29/25 - 3/4/26

Deadline

June 26 2026

Learn More

19

Days Left

POET

POET Technologies Inc.

Deadline

June 29 2026

Class Period

4/1/26 - 4/27/26

Allegations

(1) POET Technologies misrepresented its tax status due to it likely being deemed a passive foreign investment company under U.S. tax laws which, if not properly reported by each U.S. stockholder, would have negative tax implications for those U.S. stockholders; (2) the foregoing tax issue would, if discovered, make POET Technologies a less attractive investment than it would otherwise be, thus threatening POET Technologies’ valuation; (3) defendant, despite affirming that he was not violating a non-disclosure agreement, in fact violated a business agreement by speaking about POET Technologies’ business agreements in a public interview, thus endangering POET Technologies’ business prospects, and (4) as a result, defendants’ statements about POET Technologies’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

4/1/26 - 4/27/26

Deadline

June 29 2026

Learn More

26

Days Left

GPK

Graphic Packaging Holding Company

Deadline

July 6 2026

Class Period

2/4/25 - 2/2/26

Allegations

(i) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (ii) defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company’s business and financial results; (iii) defendants likewise overstated the strength and sustainability of the Company’s business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (iv) accordingly, the Company’s previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/4/25 - 2/2/26

Deadline

July 6 2026

Learn More

26

Days Left

FSK

FS KKR Capital Corp

Deadline

July 6 2026

Class Period

5/8/24 - 2/25/26

Allegations

(1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company’s portfolio valuation process; (3) the Company overstated the durability of its quarterly distribution strategy; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/8/24 - 2/25/26

Deadline

July 6 2026

Learn More

33

Days Left

PHR

Phreesia, Inc.

Deadline

July 13 2026

Class Period

5/8/25 - 3/30/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Phreesia’s slowing demand and reduced visibility in key revenue streams, notably, the weakened pharmaceutical marketing commitments in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027 guidance. The Company attributed the shortfall against its prior guidance to a combination of macroeconomic factors including “worsening visibility” and weaker pharmaceutical marketing commitments within its Network Solutions segment. Following this news, the price of Phreesia’s common stock declined from a closing market price of $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, a decline of about 27%.

Class Period

5/8/25 - 3/30/26

Deadline

July 13 2026

Learn More

37

Days Left

CVLT

Commvault Systems, Inc.

Deadline

July 17 2026

Class Period

4/29/25 - 1/26/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Commvault’s ARR growth environment; pertinently, Commvault knew or recklessly disregarded that the Company’s ARR growth guidance failed to properly factor in crucial variables, such as the type of sale. On January 27, 2026, Commvault published third quarter 2026 fiscal results, which included ARR growth below the guidance provided by the Company. In particular, ARR growth for the third quarter 2026 was $39 million, which fell short of the $45 million projection provided. Following this news, the price of Commvault’s common stock declined dramatically. From a closing market price of $129.36 per share on January 26, 2026, Commvault’s stock price fell to $89.13 per share on January 27, 2026, a decline of over 31% in a single day.

Class Period

4/29/25 - 1/26/26

Deadline

July 17 2026

Learn More

37

Days Left

SRAD

Sportradar Group AG

Deadline

July 17 2026

Class Period

11/7/24 - 4/21/26

Allegations

(1) Sportradar intentionally worked with black-market gambling operators to increase its revenues, despite its assurances of strict legal and regulatory compliance and claims that ethics and integrity were crucial for Sportradar’s operations; (2) the Company’s know-your-customer and compliance processes were not as robust as defendants’ had claimed; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

Class Period

11/7/24 - 4/21/26

Deadline

July 17 2026

Learn More

40

Days Left

VERI

Veritone, Inc.

Deadline

July 20 2026

Class Period

10/14/25 - 4/14/26

Allegations

(1) the Company inaccurately recorded and/or misclassified certain revenue and costs; (2) as a result, the Company overstated its revenue, assets, accounts receivable, royalties and other comprehensive income; (3) Veritone maintained deficient internal controls over accounting and financial reporting; (4) as a result of the foregoing, the Company would be forced to restate certain of its financial statements, and (5) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

10/14/25 - 4/14/26

Deadline

July 20 2026

Learn More

47

Days Left

ZTS

Zoetis Inc.

Deadline

July 27 2026

Class Period

1/14/25 - 5/6/26

Allegations

(i) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.

Class Period

1/14/25 - 5/6/26

Deadline

July 27 2026

Learn More

47

Days Left

CALX

Calix, Inc.

Deadline

July 27 2026

Class Period

1/28/26 - 4/21/26

Allegations

(1) the Company’s first quarter margins had significantly benefited from advanced purchasing of memory components; (2) the Company’s advanced supply of memory components was dwindling; (3) as a result, the Company was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

1/28/26 - 4/21/26

Deadline

July 27 2026

Learn More

47

Days Left

AVAV

AeroVironment, Inc.

Deadline

July 27 2026

Class Period

6/25/25 - 3/10/26

Allegations

(i) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the U.S. Space Force’s Satellite Communication Augmentation Resource program and the U.S. Space Force’s ongoing efforts to modernize the Satellite Control Network; (ii) accordingly, defendants overstated AeroVironment’s business and financial prospects; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

6/25/25 - 3/10/26

Deadline

July 27 2026

Learn More

48

Days Left

LCID

Lucid Group, Inc.

Deadline

July 28 2026

Class Period

2/25/26 - 4/13/26

Allegations

(i) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company’s business and financial results; (iii) accordingly, the defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/25/26 - 4/13/26

Deadline

July 28 2026

Learn More

54

Days Left

BMI

Badger Meter, Inc.

Deadline

August 3 2026

Class Period

4/18/24 - 4/16/26

Allegations

According to the filed complaint, defendants made false statements concerning the drivers of Badger Meter’s “record” financial results, demand for the Company’s products, and its prospects for continued growth. During the class period, defendants told investors that Badger Meter’s strong financial results reflected “ongoing favorable industry trends,” “secular growth drivers,” and “solid operating execution.” They likewise touted “strong” demand and said they were seeing “robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth,” and that Badger Meter possessed a “long runway” for growth.

Class Period

4/18/24 - 4/16/26

Deadline

August 3 2026

Learn More

54

Days Left

WGS

GeneDx Holdings Corp.

Deadline

August 3 2026

Class Period

4/16/25 - 5/4/26

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Throughout the class period, WGS repeatedly made statements that would have caused the average investor to believe that the Fabric acquisition would improve the Company’s financials and create efficiencies between it and the Company’s core business. These statements include such statements such as: “There is room to run in terms of reducing COGS in the future by combining the best of capability between GeneDx and Fabric as we lean into the best possible algorithms to optimize dry lab processes.” These and similar statements made throughout the Class Period were false. In truth, defendants knew of, or recklessly disregarded, significant problems in Fabric’s viability that would negatively impact WGS’s overall business and operations. As a result, the Company’s statements concerning its business, operations, and prospects lacked a reasonable factual basis, and shares of WGS common stock traded at artificially inflated prices during the Class Period.

Class Period

4/16/25 - 5/4/26

Deadline

August 3 2026

Learn More

54

Days Left

HELE

Helen of Troy Limited

Deadline

August 3 2026

Class Period

4/24/24 - 10/8/25

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that evidence suggests that given the importance of project pegasus to the Company’s business model and finances, the external macroeconomic conditions during the class period, and the Company’s internal budget and resource constraints, at the time these statements were made, defendants knew or should have known that project pegasus would not, and was not on track to, realize the savings, efficiency, or effectiveness that Helen of Troy consistently touted.

Class Period

4/24/24 - 10/8/25

Deadline

August 3 2026

Learn More

55

Days Left

GRAL

GRAIL, Inc.

Deadline

August 4 2026

Class Period

5/13/25 - 2/19/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL’s NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable. Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial’s end had been reduced. On February 19, 2026, GRAIL announced that the “primary endpoint of statistically significant Stage III-IV reduction was not observed” in the NHS-Galleri Trial. The Company attributed this shortcoming, in part, on “probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.” Following this news, the price of GRAIL’s common stock declined dramatically. From a closing market price of $101.53 per share on February 19, 2026, Grail’s stock price fell to $50.21 per share on February 20, 2026, a decline of about 50.55% in the span of just a single day.

Class Period

5/13/25 - 2/19/26

Deadline

August 4 2026

Learn More

55

Days Left

PICS

PicS N.V.

Deadline

August 4 2026

Class Period

This lawsuit is on behalf of all persons or entities who purchased PicS Class A common stock in and/or traceable to PicS’ January 30, 2026 initial public offering.

Allegations

(i) PicS N.V. had conducted an evaluation of its credit evaluation procedures in December 2025 and determined that such procedures were deficient and in need of enhancement; (ii) as a result of the new procedures PicS N.V. had implemented in December 2025, PicS N.V. had reclassified approximately R$590 million of exposures previously classified as Stage 2 to Stage 3, leading to an incremental ECL charge of R$88 million in the three months ended December 31, 2025; (iii) PicS N.V. had experienced a heightened, but unreported, Stage 3 formation rate of more than 7% in the fourth quarter of 2025 that deviated substantially from the historical results and trends provided in the offering documents; (iv) the IPO's offering documents had materially overstated the quality and ability of PicS N.V.'s credit models and user data to inform PicS N.V.'s underwriting practices and to allow PicS N.V. to timely and effectively monitor, assess, and identify adverse credit events, credit risks, and credit deterioration across its portfolio; and (v) PicS N.V. suffered from degradations in customer credit quality and heightened risks of default and loan impairment as a result of its entrance into materially riskier business lines leading up to the IPO, resulting in undisclosed adverse financial and operational trends such as heightened incidents of default, which predated the IPO and were internally projected by PicS N.V. to continue to worsen following the IPO, materially impairing PicS N.V.'s business, operations, and financial results.

Class Period

This lawsuit is on behalf of all persons or entities who purchased PicS Class A common stock in and/or traceable to PicS’ January 30, 2026 initial public offering.

Deadline

August 4 2026

Learn More

55

Days Left

VRRM

Verra Mobility Corporation

Deadline

August 4 2026

Class Period

2/24/26 - 5/26/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra’s relationship with Avis Budget Group (“Avis”), and in particular obtaining a contract extension with Avis. Further, the Company minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives. On May 26, 2026, Verra issued a press release announcing a termination notice from Avis regarding its contract and accordingly lowered its 2026 full-year financial outlook. Almost one week later on June 1, 2026, the Company announced a sudden and surprising transition of its President and Chief Executive Officer David Roberts. Following this news, the price of Verra’s common stock declined dramatically. From a closing market price of $13.08 per share on May 26, 2026, Verra’s stock price fell to $3.85 per share on May 27, 2026, a decline of about 71%.

Class Period

2/24/26 - 5/26/26

Deadline

August 4 2026

Learn More

58

Days Left

BTGO

BitGo Holdings, Inc.

Deadline

August 7 2026

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired (a) BitGo Class A common stock pursuant and/or traceable to the offering documents issued in connection with the Company’s January 22, 2026 initial public offering; and/or (b) BitGo securities between January 22, 2025 and May 13, 2026, both dates inclusive.

Allegations

(i) defendants understated the scope and severity of the risk that declining digital asset prices posed to Company’s business and financial performance; (ii) consequently, defendants’ statements regarding, inter alia, BitGo’s financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the offering documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and/or failed to state information required to be stated therein.

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired (a) BitGo Class A common stock pursuant and/or traceable to the offering documents issued in connection with the Company’s January 22, 2026 initial public offering; and/or (b) BitGo securities between January 22, 2025 and May 13, 2026, both dates inclusive.

Deadline

August 7 2026

Learn More

58

Days Left

RBLX

Roblox Corporation

Deadline

August 7 2026

Class Period

10/30/25 - 4/30/26

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox’s organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. On April 30, 2026, Roblox announced its financial results for the first quarter of fiscal 2026. Management slashed bookings growth guidance down to 8-12% and a corresponding decline to margin expectations. Defendants disclosed the age verification rollout had caused much more significant impacts to engagement and organic growth than management had previously suggested and age check adoption had only increased to 51% global daily active users, from 45% at the end of the previous quarter. Following this news, the price of Roblox’s common stock declined dramatically. From a closing market price of $55.26 per share on April 30, 2026, Roblox’s stock price fell to $45.13 per share on May 1, 2026, a decline of about 18.33% in the span of just a single day.

Class Period

10/30/25 - 4/30/26

Deadline

August 7 2026

Learn More

View All Deadlines

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Globant Hit With Investor Suit Over Latin America Turmoil
Globant told investors Latin America was its next big success story. A $1 billion expansion. Strong demand. Rapid growth. A rising footprint across Brazil, Mexico, and Argentina. But shareholders allege the reality looked very different. The lawsuit says Globant was actually facing declining demand, canceled projects, and clients walking away. In Brazil, its big acquisition...Read more

June 10, 2026

Learn More

LKQ Shareholders Allege Defendants Drove Stock Price Into the Junkyard
LKQ told investors its $2.1 billion Uni-Select deal, including FinishMaster, would drive growth and strengthen its market position. According to the complaint, LKQ called it a “compelling strategic fit” with minimal integration risk. But the lawsuit says, FinishMaster was already losing major customers and market share. Investors allegedly had no idea. In February 2023, LKQ...Read more

June 9, 2026

Learn More

B&W Shareholders Sue Over Alleged Contract Conflicts
Babcock & Wilcox told investors it had landed a transformational AI data center power deal worth over $1.5 billion. Then that story got even bigger, with executives raising it to a $2.4 billion contract and pointing to backlog and demand. But investors later learned allegations that cast the deal in a very different light. In...Read more

June 8, 2026

View All News

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys